{"id":"NCT01296412","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)","officialTitle":"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-11","primaryCompletion":"2012-02-29","completion":"2012-02-29","firstPosted":"2011-02-15","resultsPosted":"2013-03-15","lastUpdate":"2017-06-09"},"enrollment":653,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"sitagliptin","otherNames":["MK-0431, Januvia®, Tesavel®, Xelevia®, Ristaben®"]},{"type":"DRUG","name":"liraglutide","otherNames":["Victoza®"]},{"type":"DRUG","name":"glimepiride","otherNames":["Amaryl®"]},{"type":"DRUG","name":"metformin","otherNames":["Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®"]}],"arms":[{"label":"Sitagliptin +/- glimepiride","type":"EXPERIMENTAL"},{"label":"Liraglutide","type":"ACTIVE_COMPARATOR"}],"summary":"This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with Type 2 Diabetes that is not adequately controlled with metformin alone. The primary hypothesis postulated that the mean change from baseline in hemoglobin A1c (A1C) in participants treated with a sitagliptin-based treatment is non-inferior to that of participants treated with a liraglutide-based\n\ntreatment.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (A1C)","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Sitagliptin +/- Glimepiride","deltaMin":-1.32,"sd":1.06},{"arm":"Liraglutide","deltaMin":-1.42,"sd":1.04}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23604551"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":326},"commonTop":["Nausea","Hypoglycaemia","Diarrhoea","Vomiting","Decreased appetite"]}}